Regeneus Ltd.
Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain. Pain and inflammation are responsible for a series of events leading to immune cells reacting to damaged tissue, causing chronic and acute illness. The Company develops regenerative medicine products that interrupt the inflammatory cascade that leads to pain, including its two leading stem cell technologies, Progenza - which has been licenced to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus - which is in pre-clinical stage.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About Us
At Regeneus we pride ourselves in our ability to create research collaborations and further our knowledge to advance our therapies. By creating scientific communities we have been able to advance our methods and quality selection criteria to obtain highly scalable and highly potent products. Through scientific co-creation we are advancing the field of pain therapy and providing relief to millions of people around the world.
Our History
Regeneus was founded in 2007 and listed on the Australian Securities Exchange (ASX) in September 2013. In 2019, Regeneus consolidated the company's strategic direction to target the global pain market with an initial focus on its lead platform technology, Progenza™.
A Pioneer in Cell therapy treatment Regeneus began our mission in autologous cell therapy for patients suffering from arthritis, we utilized our experience and knowledge to shift to innovative allogeneic cell therapy for broader application, democratizing MSCs for the treatment of pain for millions of everyday people.